Loading…
Company strengthens financial position and receives significant product demand.
Trinity Biotech plc announced on 2025-12-23 Trinity Biotech plc has entered into agreements with funds managed by Perceptive Advisors to enhance its financial flexibility and optimize its capital structure, including a new $5 million term-loan, up to $60 million in elective equitization capacity, and equity settlement mechanisms for milestone payments and contingent obligations. Additionally, Trinity Biotech has received a major order for 9 million units of its flagship HIV screening product, TrinScreen HIV, signaling renewed strength in the global HIV testing market.
The announcement cited $5 million, up to $60 million, $5 million milestone payments, $7.5 million contingent obligations, $14.3m, $10.8m, $2.1m, $3.6m, $4.0m, $5.7m, $6.5m, $4.6m, $0.5 million, negative $2.1m, and 9 million units.
Trinity Biotech plc has a free float of 325,114,000 shares and 18,632,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.